Jessica Garcia
Family · Edinburg, TXNPI 1124321096
Payments from drug & device makers
Across 374 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$876
- GSK$487
- Lilly USA, LLC$459
- Boehringer Ingelheim$410
- Otsuka America Pharmaceutical, Inc.$407
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,16799%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $1,868 |
| Novo Nordisk | 66 | $876 |
| GSK | 26 | $487 |
| Lilly USA, LLC | 34 | $459 |
| Boehringer Ingelheim | 20 | $410 |
| Otsuka America Pharmaceutical, Inc. | 22 | $407 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $405 |
| AstraZeneca | 10 | $361 |
| AbbVie | 19 | $356 |
| Ironwood Pharmaceuticals, Inc | 18 | $301 |
| Astellas Pharma US Inc | 17 | $299 |
| Pfizer | 8 | $144 |
| Johnson & Johnson | 7 | $137 |
| Dexcom, Inc. | 2 | $128 |
| Amarin Pharma, Inc. | 7 | $115 |
| Amgen | 7 | $102 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Atricure, Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Optinose US, Inc. | 2 | $42 |
| Bayer | 2 | $42 |
| Ardelyx, Inc. | 1 | $28 |
| Novartis | 2 | $27 |
| Redhill Biopharma Inc. | 2 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$284
- Proclaim IPG$268
- FARXIGA$141
- RYBELSUS$124
- DEXCOM G7 GSS (161)$112
How this compares
$7,252 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $89,613 |
| LinzessLinaclotide | 67 | $61,593 |
| FarxigaDapagliflozin Propanediol | 52 | $57,026 |
| JardianceEmpagliflozin | 41 | $54,353 |
| MyrbetriqMirabegron | 38 | $44,707 |
| MounjaroTirzepatide | 39 | $43,182 |
| TrulicityDulaglutide | 22 | $33,855 |
| JanuviaSitagliptin Phosphate | 14 | $22,085 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,890 |
| EliquisApixaban | 13 | $20,295 |
| GemtesaVibegron | 15 | $18,675 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $12,938 |
| XareltoRivaroxaban | 13 | $12,643 |
| Pregabalin | 77 | $4,927 |
| Atorvastatin Calcium | 359 | $2,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $876 | $89,61383 claims |
| Lilly USA, LLCMounjaro, Trulicity | $459 | $77,03761 claims |
| AbbVieLinzess | $356 | $61,59367 claims |
| AstraZenecaFarxiga | $361 | $57,02652 claims |
| Boehringer IngelheimJardiance | $410 | $54,35341 claims |
| Astellas Pharma US IncMyrbetriq | $299 | $44,70738 claims |
| GSKTrelegy Ellipta | $487 | $21,89033 claims |
| PfizerEliquis | $144 | $20,29513 claims |
| Johnson & JohnsonXarelto | $137 | $12,64313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Edinburg
- Mayra CantazaroEdinburg$150K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.